N-[(3S,5S)-1-(2H-1,3-benzodioxol-5-ylmethyl)-5-(piperazine-1-carbonyl)pyrrolidin-3-yl]-N-[(3-methoxyphenyl)methyl]-3,3-dimethylbutanamide

• ChemBase ID: 165046
• Molecular Formular: C31H42N4O5
• Molecular Mass: 550.68898
• Monoisotopic Mass: 550.31552046
• SMILES: C1[C@H](N(C[C@H]1N(C(=O)CC(C)(C)C)Cc1cccc(c1)OC)Cc1ccc2c(c1)OCO2)C(=O)N1CCNCC1
• Canonical SMILES: COc1cccc(c1)CN(C(=O)CC(C)(C)C)[C@H]1C[C@H](N(C1)Cc1ccc2c(c1)OCO2)C(=O)N1CCNCC1
• InChI: InChI=1S/C31H42N4O5/c1-31(2,3)17-29(36)35(19-22-6-5-7-25(14-22)38-4)24-16-26(30(37)33-12-10-32-11-13-33)34(20-24)18-23-8-9-27-28(15-23)40-21-39-27/h5-9,14-15,24,26,32H,10-13,16-21H2,1-4H3/t24-,26-/m0/s1
• InChIKey: WPHXYKUPFJRJDK-AHWVRZQESA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: N-[(3S,5S)-1-(2H-1,3-benzodioxol-5-ylmethyl)-5-(piperazine-1-carbonyl)pyrrolidin-3-yl]-N-[(3-methoxyphenyl)methyl]-3,3-dimethylbutanamide
• IUPAC Traditional name: N-[(3S,5S)-1-(2H-1,3-benzodioxol-5-ylmethyl)-5-(piperazine-1-carbonyl)pyrrolidin-3-yl]-N-[(3-methoxyphenyl)methyl]-3,3-dimethylbutanamide
• Synonyms: N-[(3S,5S)-1-(1,3-Benzodioxol-5-ylmethyl)-5-(1-piperazinylcarbonyl)-3-pyrrolidinyl]-N-[(3-methoxyphenyl)methyl]-3,3-dimethylbutanamide; CUR 61414

Database IDs

• CAS Number: 334998-36-6
• PubChem SID: 162259179
• PubChem CID: 10392802

CALCULATED PROPERTIES

• H Acceptors: 7
• H Donor: 1
• LogD (pH = 5.5): -0.7034338
• LogD (pH = 7.4): 2.1798923
• Log P: 2.82501
• Molar Refractivity: 152.7528 cm^3
• Polarizability: 60.220734 Å^3
• Polar Surface Area: 83.58 Å^2
• Rotatable Bonds: 9
• Lipinski's Rule of Five: false

PROPERTIES

Physical Property

• Solubility: Chloroform; Methanol
• Apperance: Pale Yellow Solid
• Melting Point: 35-40°C

Safety Information

• Storage Condition: Hygroscopic, -20°C Freezer, Under Inert Atmosphere

DETAILS

Toronto Research Chemicals - C835000

CUR 61414 is a proline derivative as mediator of hedgehog signaling pathways for pharmaceutical and cosmetic uses. CUR 61414 is a Nucleoside analog. CUR 61414 is an antimetabolite antitumor combination Gemcitabine cancer treatment.

REFERENCES

• Van der Riet, P., et al.: Cancer Res., 54, 25 (1994)
• Hahn, H., et al.: Cell, 85, 841 (1994)
• Johnson, R., et al.: Science, 272, 1668 (1994)
• Ingham, P., et al.: Genes Dev., 15, 3059 (1994)